India struck down a patent covering GlaxoSmithKline's breast-cancer drug Tykerb over concerns that the treatment is not innovative enough to deserve its own patent. A GSK representative said the company was evaluating an appeal. Similarly, a Roche representative confirmed that India had canceled divisional patents for the company's breast cancer treatment Herceptin over improper patent submissions.

Related Summaries